MPC-2130

    WARNING: This product is for research use only, not for human or veterinary use.

Description: MPC-2130 is a broad-acting, apoptosis-inducing, small molecule with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, apoptosis inducer MPC-2130 exhibits proapoptotic activities in tumor cells, including membrane phosphatidylserine externalization, release of cytochrome C from mitochondria, caspase activation, cell condensation, and DNA fragmentation. In addition, because this agent is not a substrate for several types of multidrug resistance (MDR) ABC superfamily transporters, such as P-glycoprotein 1 (MDR-1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance protein 1 (BCRP1/ABCG2), it may be useful in treating MDR tumors that express these particular MDR efflux pumps. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Price and Availability

MPC-2130 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: MPC2130; MPC-2130; MPC 2130.

IUPAC/Chemical Name: NONE

Technical Data

Additional Information

MPC-2130 was discovered at Myriad Pharmaceuticals, Inc. as a result of an extensive medicinal chemistry effort. The original lead compound, from which MPC-2130 was derived, was discovered in a yeast-based high throughput screen. Tumor cells treated with MPC-2130 display multiple indicators of apoptotic cell death, that include phosphatidylserine flipping to the outer cell membrane, release of cytochrome C from the mitochondria, caspase activation, cell condensation and DNA fragmentation.  Research results suggest that MPC-2130 may be an effective therapy against multiple tumor types in humans. see Christopher Pleiman, Kimberly Mauck, Lynn Demie, Orvelin Roman, Lori Fotheringham, Daniel Von Hoff, Adrian Hobden, Robert Carlson and Gary Mather; Antitumor activity of MPC-2130 in human ovarian and prostate tumor xenografts in athymic nude mice; [Proc Amer Assoc Cancer Res, Volume 46, 2005; http://www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/151-c.
MPC-2130 was discovered at Myriad Pharmaceuticals, Inc. as a result of an extensive medicinal chemistry effort. The original lead compound, from which MPC-2130 was derived, was discovered in a yeast-based high throughput screen. Tumor cells treated with MPC-2130 display multiple indicators of apoptotic cell death, that include phosphatidylserine flipping to the outer cell membrane, release of cytochrome C from the mitochondria, caspase activation, cell condensation and DNA fragmentation.  Research results suggest that MPC-2130 may be an effective therapy against multiple tumor types in humans. see Christopher Pleiman, Kimberly Mauck, Lynn Demie, Orvelin Roman, Lori Fotheringham, Daniel Von Hoff, Adrian Hobden, Robert Carlson and Gary Mather; Antitumor activity of MPC-2130 in human ovarian and prostate tumor xenografts in athymic nude mice; [Proc Amer Assoc Cancer Res, Volume 46, 2005; http://www.aacrmeetingabstracts.org/cgi/content/abstract/2005/1/151-c.
 
 

References